Qvar
Product Images NDC 16590-860

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Qvar (NDC 16590-860). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Qvar 40mcg Lab 860)

QVAR 40 mcg metered inhalation aerosol label by STAT RX USA LLC. The label states the product strength as 40 mcg with a net weight of 7.3 g. It indicates that each inhalation delivers 40 mcg of beclomethasone dipropionate. The label mentions the product NDC as 16590-860-71 and includes manufacturer information for Teva Specialty Pharmaceuticals LLC. There is a caution note to see the package insert and a warning to keep the product out of reach of children.*

FDA Label Image

Chemical Structure (Qvar 01)

Chemical structure of the active ingredient in QVAR, a corticosteroid. The structure shows a steroid backbone with hydroxyl, chloro, and ester functional groups attached.*

FDA Label Image

6-week Graph (Qvar 02)

A line graph showing mean change in AM PEF (L/min) over treatment weeks for QVAR 40 mcg twice daily, QVAR 80 mcg twice daily, and HFA-134a placebo. The x-axis represents weeks 1 to 6, and the y-axis represents change in AM PEF from -40 to 60 L/min.*

FDA Label Image

12-week Graph (Qvar 03)

A line graph depicting the mean AM Peak Expiratory Flow (PEF) over a 12-week period. The graph compares three treatments: QVAR 160 mcg twice daily, CFC-BDP 336 mcg twice daily, and HFA-134a placebo. The x-axis represents time points including run-in, oral steroid treatment, and weeks 1-12. The y-axis shows mean AM PEF in L/min, ranging approximately from 300 to 550.*

FDA Label Image

6-week Graph (Qvar 04)

A line graph depicting the mean change in FEV1 as a percentage of predicted values over a six-week period for various treatments. The graph compares QVAR at doses of 40, 160, and 320 mcg twice daily to CFC-BDP at doses of 142, 168, and 336 mcg twice daily, showing trends in lung function improvement across weeks.*

FDA Label Image

Figure 1 (Qvar 05)

An instructional diagram showing a hand holding a QVAR inhaler and another hand removing the mouthpiece cap. The parts labeled include the mouthpiece and cap, illustrating how to prepare the inhaler for use.*

FDA Label Image

Figure 2 (Qvar 06)

An illustration depicting a person using an inhaler, demonstrating the proper technique of inhaling medication from the device. The drawing focuses on the hand holding the inhaler and the person's face in profile.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.